SEAMUS CONNOLLY: Open Payments
NPI 1932648599 · INDIO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,308 in 124 payments from 15 companies in 2025. Trend: 2023 $1,848 · 2024 $4,216 · 2025 $3,308
Food & beverage: $3,204Education: $104
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 31 | $755 |
| Janssen Pharmaceuticals, Inc | 13 | $415 |
| Teva Pharmaceuticals USA, Inc. | 10 | $376 |
| Neurocrine BioSciences, Inc. | 8 | $373 |
| Alkermes, Inc. | 12 | $356 |
| Vanda Pharmaceuticals Inc. | 8 | $296 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $228 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $141 |
| Lundbeck LLC | 10 | $136 |
| ABBVIE INC. | 4 | $100 |
Products named: REXULTI, INGREZZA, FANAPT, AUSTEDO XR, INVEGA SUSTENNA, ARISTADA, CAPLYTA, TRINTELLIX.
Industry payments across CA — which companies pay providers there.
